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Conditions in which antidepressants have been used include diabetic neuropathy, 
postherpetic neuralgia, headaches, arthritis, chronic back pain, cancer, thalamic 
pain, facial pain, and phantom limb pain. Although much of the available informa- 
tion is derived from inadequately controlled trials, it seems that antidepressants 
provide analgesia in many of these disorders. The analgesic effects tend to be 
independent of antidepressant effects, and doses of heterocyclic antidepressants 
used for analgesia seem to be lower than those considered effective in the treat- 
ment of depression. Doses should be started low and gradually increased until the 
patient reaches the highest tolerable dose. Onset of analgesia is variable, ranging 
from 1 day to 10 weeks. Common side effects include dry mouth, drowsiness, 
urinary retention, orthostatic hypotension, and constipation. Optimum dosages 
and schedules have not been established. 
(Pharmacotherapy 1990;10(4):262-270) 
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Conclusion 
Antidepressant agents such as amitriptyline, nor- 
triptyline, imipramine, desipramine, doxepin, trimi- 
pramine, and trazodone have been used in the treat- 
ment of various chronic pain conditions. These 
agents are known as heterocyclic antidepressant 
agents (HCAs). Although the biochemical mecha- 
nisms of analgesia appear theoretically sound, clini- 
cal evidence supporting the efficacy of HCAs as an- 
algesics is mainly anecdotal. Few controlled studies 
provide data on appropriate indications, optimum 
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dosages, or the relative efficacy of available agents. 
Pathways and Mechanisms of Pain Transmission 
The transmission, modulation, and perception of 
pain involve several pathways. Afferent pathways 
carry sensory input of painful stimuli; efferent path- 
ways modulate pain transmission.’ Afferent path- 
ways originate in peripheral pain receptors (noci- 
ceptors). Sensory neurons carry pain impulses from 
these nociceptors to the dorsal horn of the spinal 
cord, forming synapses with spinal neurons. Pain 
fibers then travel by way of ascending spinal tracts 
to the brain for perception. Pain impulses carried by 
the afferent fibers are modulated by three major 
 mechanism^.'-^ 
The first mechanism is known as gate control: 
pain transmission to the central nervous system is 
mediated by small myelinated and unmyelinated 
nerve fibers3, Sensory input to these fibers is mod- 
ulated by larger unmyelinated nerve fibers with the 
capacity for fast impulse transmission. The second 
mechanism involves the sympathetic nervous sys- 
tem, which modulates the transmission of pain in a 
manner that is poorly understood. 
Descending or efferent pathways are the third and 
probably the major mechanism of pain modulation. 
Efferent pathways extend from the cerebral cortex to 
the dorsal horn of the spinal cord. Transmission of 
pain by afferent pathways is modulated through 
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powerful inhibitory processes in the dorsal horn that 
are activated by the release of endogenous opiate 
substances (enkephalins and  endorphin^).'-^ In ad- 
dition, the neurons of the descending pathways re- 
lease serotonin, dopamine, norepinephrine, and 
other neurotransmitters that cause the release of 
endorphins and enkephalins. This appears to be the 
site where antidepressant agents act to modulate 
pain.23 Stimulation of the nucleus raphe magnus, an 
area of the brain rich in serotonin, results in analge- 
sia, whereas serotonin deficiency results in hyperal- 
gesia.'j-12 
Types of Pain 
Important differences exist between acute and 
chronic pain. Acute pain is typically associated with 
acute disease or l 4  Its biologic function is to 
warn one of tissue damage. It has a well-defined 
temporal onset and usually subsides as healing pro- 
gresses. Chronic pain may appear when an acute 
pain episode does not resolve in the expected time, 
or when pain emerges with no definite precipitating 
factor. It may persist for months or years13-16 and, 
unlike acute pain, serves no biologic function. 
A number of psychologic variables must be con- 
sidered when treating patients with chronic pain. 
Many experts believe that there is a definite psycho- 
logic profile of individuals who are prone to the idio- 
pathic pain syndrome or so-called psychogenic 
pain d i~0rder . l~  This theory suggests that chronic 
pain is a somatic symptom of an underlying depres- 
sive disorder and that treatment of the depression 
results in pain relief.l77l8 Chronic pain and depres- 
sion are closely related; it is often difficult to identify 
which came f i r ~ t . ' ~ - ~ ~  Evidence shows that the bio- 
chemical mechanisms of the two are linked.25,26 
Some investigators, however, believe that depres- 
sion associated with chronic pain is the result of an 
adjustment disorder that is not biochemically medi- 
ated and therefore not likely to respond to treatment 
with HCAS.~', 28 Successful management of chronic 
pain must include evaluation and treatment of any 
accompanying psychologic 
Mechanism of Action of Antidepressants 
The HCAs inhibit reuptake of serotonin, norepi- 
nephrine, or both by the presynaptic neuron. This 
prolongs the availability of neurotransmitter within 
the synapse so that it can stimulate receptors on the 
postsynaptic n e u r ~ n . ~ ~ - ~ ~  The mechanism by which 
HCAs relieve depression may be related to the in- 
creased availability of neurotransmitters; however, it 
is not completely understood. 
The mechanism by which HCAs provide analge- 
sia is also controversial. Some investigators postu- 
late an antidepressant 34 whereas others 
Seem to suggest a direct analgesic action separate 
from the antidepressant effect.5, 35 Direct analgesic 
action is suggested by studies in which the onset of 
analgesia was more rapid than would be expected 
for an antidepressant e f f e ~ t , ~ ~ ? ~ ~  and by trials in 
which analgesia was reported in the absence of anti- 
depressant e f f e ~ t . ~ ~ - ~ ~  Experiments in laboratory ani- 
mals showed that a prolonged availability of sero- 
tonin at the neuronal synapse increases the pain 
threshold.35 The HCAs also have been shown to 
potentiate the effect of narcotic analgesics in ani- 
mals and  human^.^^-^^ 
Problems arise in evaluating literature describing 
the use of antidepressants as analgesics. Patients 
with chronic pain have a high rate of response to 
placebo47; therefore, the results of studies lacking 
appropriate controls must be questioned. In addi- 
tion, it is difficult to distinguish the reason for re- 
sponse to analgesics in patients with primary de- 
pressive disorders (with pain as an initial symptom) 
from that in patients who primarily have chronic pain 
(which results in situational or reactive depres- 
s i ~ n ) . ~ ~ ~  28 
The HCAs have been used as analgesics in pain- 
ful diabetic neuropathy, postherpetic neuralgia, ten- 
sion and migraine headaches, arthritis pain, chronic 
back pain, cancer, and other painful disorders. They 
also have been employed against thalamic pain,", 49 
facial pain,50 and phantom limb ~ a i n , ~ l - ~ *  but insuffi- 
cient data prevent critical evaluation of their efficacy 
for such uses. 
Neurologic Pain 
Pain resulting from peripheral nerve damage is 
particularly difficult to treat. In this condition, called 
deafferentation pain, the pain-conduction pathways 
are interrupted, making the usual methods of pain 
control U ~ S U C C ~ S S ~ U ~ . ~ ~ ~  54 The mechanism by which 
antidepressants act in this syndrome is unknown. 
Diabetic Neuropathy 
The pathophysiologic mechanisms involved in 
painful diabetic neuropathy (PDN) have yet to be 
elucidated. Postulated mechanisms include ische- 
mia-induced damage to nerve fibers, nerve com- 
pression, and immunologic and biochemical de- 
rangements. Damaged efferent nerve fibers may 
generate abnormal impulses or alter the excitability 
of mechanoreceptors (receptors that respond to 
mechanical pressures), resulting in neuropathic 
The pain is often characterized as lancinat- 
ing, burning, sharp, shooting, and biting. The HCAs 
have been widely used in the management of PDN. 
Davis et al first reported beneficial results from 
antidepressants in the management of PDN.36 In 
their series of uncontrolled case reports, a combina- 
tion of amitriptyline 75 mg daily and fluphenazine 3 
mg daily, or fluphenazine alone relieved pain within 
5 days after initiation of therapy in three patients. A 
beneficial response also was reported in eight pa- 
tients with the combination of an HCA and phenothi- 
Investigators using a combination of HCA and 
neuroleptic were unable to document similar onset 
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of relief in two controlled ~ t u d i e s . ~ ~ . ~ ~  In a crossover 
study, six patients who were treated with amitripty- 
line 75 mg daily and fluphenazine 3 mg daily had no 
improvement in pain compared to placebo after the 
15-day A study of 24 patients comparing the 
combination of nortriptyline 10-20 mg three times 
daily and fluphenazine 0.5-1 .O mg three times daily 
to placebo59 showed no decrease in pain or pares- 
thesia after 15 days of therapy; significant de- 
creases in pain (p < 0.01) and paresthesia (p < 
0.001) were seen after 30 days. 
The HCAs also have been used alone for the treat- 
ment of PDN. In a series of case reports, 58 of 80 
patients had some relief of symptoms with imipra- 
mine 50-1 50 mg at bedtime (n = 43), mianserin (an 
investigational tetracyclic antidepressant) 30-90 mg 
at bedtime (n = 6), or amitriptyline 50-150 mg at 
bedtime (n = 9).57 Dramatic relief of pain was docu- 
mented with trazodone 100 mg daily in five of six 
patients.60 
Amitriptyline 100 mg at bedtime (n = 19), imipra- 
mine 100 mg at bedtime (n = 20), and diazepam 5 
mg three times daily (n = 20) were compared in 
patients with PDN.33 All 39 patients treated with 
HCAs experienced complete relief after a 3-month 
trial; no relief was reported with diazepam. The aver- 
age onset of analgesia was 10 weeks, and pain relief 
correlated well with normalization of depression 
scores. The author concluded that HCAs relieve the 
pain of diabetic neuropathy by virtue of their anti- 
depressant effect. In a double-blind, crossover 
study, imipramine 25-1 50 mg daily was compared 
to placebo in six patients with PDN who had pre- 
viously responded to imipramine in an open 
All patients reported decreased pain with imipra- 
mine, with a mean onset of one day. No attempt was 
made to correlate analgesia with mood changes. 
Amitriptyline 25-1 50 mg at bedtime was more ef- 
fective than placebo in producing analgesia in 29 
patients with PDN; there was no correlation between 
antidepressant effect and analgesia.38 The analge- 
sia described by nondepressed patients was similar 
to that in depressed patients, and it occurred in 
some depressed patients without associated 
changes in mood. The average onset of analgesia 
was 3 weeks. Similar results were achieved in a 5- 
week comparison of imipramine 100 mg daily to 
placebo in 12 nondepressed patients with PDN.61 
Pain was relieved more often with imipramine than 
placebo, with average onset of 1 week. 
The rapid onset of action of combination HCA- 
phenothiazine therapy reported in early anecdotes 
may have been due to a placebo effect. The HCAs 
may be more effective than placebo in providing 
analgesia in PDN, with onset of 1-1 0 weeks. In gen- 
eral, analgesic doses are lower than those neces- 
sary for antidepressant effect.62 Trials have reported 
efficacy with daily doses of imipramine ranging from 
25-1 50 mg, amitriptyline 25-1 50 mg, and nortripty- 
line 20-60 mg. Adverse effects of HCAs such as dry 
mouth, drowsiness, and urinary retention are com- 
mon and may be minimized with slow upward titra- 
tion of the dose. Currently, no controlled trials sup- 
port the addition of a phenothiazine to an HCA in the 
treatment of PDN. 
Postherpetic Neuralgia 
The gate control theory of pain perception seems 
to explain best the intractable nature of postherpetic 
neuralgia (PHN) .63 Acute herpes zoster infections 
cause damage of large, unmyelinated nerve fibers. 
The damaged fibers regenerate slowly to form small 
nerve fibers, but lose their previous pain-modulating 
effect in the process. The net result is indiscriminate 
firing of nerve impulses by the small nerve fibers. 
Postherpetic neuralgia is characterized by its twist- 
ing, lancinating, pressing, gripping pain. Relief is 
often found in sleep. 
In a series of case reports, five patients who re- 
ceived amitriptyline 75-1 00 mg daily with either per- 
phenazine 12-1 6 mg daily, fluphenazine 4 mg daily, 
or thioridazine 100 mg daily experienced a marked 
decrease of PHN 1-2 weeks after initiation of treat- 
ment.64 Although three of these patients had had no 
relief from previous therapy with either amitriptyline 
or nortriptyline alone, the trials of single agents may 
not have been of sufficient duration. 
In a randomized, double-blind, crossover study 
amitriptyline 25-137.5 mg daily was compared to 
placebo in 24 patients with PHN.37 Pain was mea- 
sured by visual analog scale (VAS) and by verbal 
descriptors (no change, poor, good, excellent). Six- 
teen patients reported greater pain relief during ami- 
triptyline treatment than during placebo (p < 0.001). 
Fourteen of 23 patients evaluated were not de- 
pressed by Beck depression inventory; of these, l l  
noted a good to excellent response. Of the nine 
depressed patients, one had good pain relief with- 
out an antidepressant response, six had good pain 
relief with an antidepressant response, and two not- 
ed no change in'either condition. Onset of pain relief 
was not reported. As expected, the most common 
adverse effects included dry mouth, drowsiness, 
and constipation. Uncontrolled follow-up in 22 pa- 
tients after 1-19 months (median 12 mo) was also 
reported. Amitriptyline was still being taken by 7 of 
12 patients who reported continued response, but 
was being taken by only 1 of 10 without continued 
response. Thus, there appeared to be an associ- 
ation between continued amitriptyline use and pro- 
longed pain relief. The authors concluded that ami- 
triptyline is effective in PHN and that its analgesic 
effect is not related to its antidepressant activity. 
Although few controlled studies have been con- 
ducted, reports indicate that HCAs may be useful for 
PHN. The analgesic effect appears to be inde- 
pendent of the antidepressant effect. The addition of 
a phenothiazine has been reported to be effective; 
however, no controlled trials have supported this 
combination. 
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Headache 
There are three major types of headaches based 
on the etiology of pain: muscle contraction or ten- 
sion, vascular or migraine, and traction-inflamma- 
tory secondary to organic disease in the 
Continuous contractions of external cranial muscles 
as well as muscles of the neck, head, and face 
cause the dull, bilateral pain of tension head- 
a c h e ~ . ~ ~ ~ ~ ~  Stress may be a precipitating factor. Mi- 
graine headaches, on the other hand, result from 
initial vasoconstriction in the craniocerebral circula- 
tion followed by excessive vasodilation. Secondary 
vasodilation may result from a sharp drop in sero- 
tonin levels, evidenced by an increase in mono- 
amine metabolites in The HCAs may be 
beneficial in preventing this vasodilation by virtue of 
their ability to increase plasma levels of serotonin 
and monoamines, thereby preventing the vascular 
component of headache pain. Symptoms of mi- 
graine that differentiate it from other types of head- 
ache include nausea and vomiting, vision distur- 
bances, and various neurologic signs (aura). 
Although migraines are generally thought to differ 
from tension headaches, some patients have fea- 
tures of both types; these headaches are labeled 
mixed tension-vascular. Because of this blurring be- 
tween types, HCAs have been used in both condi- 
tions. Antidepressants have not been studied in the 
management of traction-inflammatory headaches. 
A placebo-controlled, crossover trial of amitripty- 
line 10-25 mg three times daily was conducted in 27 
patients with chronic headache.39 Headaches were 
not associated with migrainelike features, but some 
were thought to have a vascular component; all 
headaches were present for at least a year and oc- 
curred more than 10 times monthly. Each treatment 
period was 1 month and pain was evaluated by pa- 
tients as improved or unchanged at the end of the 
treatment period. Depression was assessed using 
the Hamilton rating scale for depression. Three pa- 
tients responded to both placebo and active treat- 
ment, 12 had no improvement during either period, 
and 12 reported a response only to amitriptyline. 
These results were significantly in favor of amitripty- 
line (p value not reported); no association between 
response and antidepressant effect was noted. 
A double-blind, randomized, crossover study 
compared the efficacy of doxepin starting with 25 
mg at bedtime and increased gradually to 100 mg 
daily to that of placebo in 23 patients with mixed 
tension-vascular  headache^.^^ Nine patients 
dropped out of the trial, four due to doxepin-related 
side effects. No significant differences were ob- 
served in the number of headache days during each 
9-week period. During doxepin treatment, however, 
there was a significant reduction (p < 0.05) in head- 
ache index, defined as the product of headache 
days times severity. In addition, the consumption of 
additional analgesics and ergotamine preparations 
was reduced in 8 of the 10 patients who recorded 
this information (p < 0.01). The authors concluded 
that doxepin should be considered as an alternative 
in the treatment of mixed tension-vascular head- 
aches. 
In a single case report, trazodone 100 mg daily 
was effective in the treatment of chronic, intractable, 
mixed tension-vascular headache.68 The patient 
was not initially depressed and had been refractory 
to other treatment for 7 years. Headaches complete- 
ly disappeared within 2 weeks of beginning treat- 
ment. 
After initial positive results were seen with the use 
of amitriptyline for headaches,39 a double-blind, 
crossover, placebo-controlled trial was conducted 
in 20 patients with migraine.69 The drug was initiated 
at a dose of 30 mg daily and titrated to a final daily 
dose of 10-60 mg usually taken at bedtime. The 
average, final dose of 30-40 mg was established by 
the fourth week and continued for the remainder of 
the 27-week study period. The frequency of mi- 
graine attacks was reduced more during drug treat- 
ment than during the placebo period in 16 of 20 
patients (p < 0.01). The total number of attacks re- 
corded by the study group was 207 during amitripty- 
line treatment compared to 356 during placebo 
treatment, a decrease of 42% (p < 0.001). 
In an uncontrolled study, 11 0 patients with mi- 
graine headaches were treated with daily doses of 
amitriptyline ranging from 25-175 mg; 90% of the 
patients received daily doses between 50 and 75 
mg.70 The frequency, duration, and severity of head- 
aches were assessed between 4 and 12 weeks of 
therapy (average 5.4 wks). Patients were also evalu- 
ated for depression before and after treatment using 
the Zung depression scale. The frequency (55%) 
and duration (60%) of headaches compared to 
baseline decreased significantly (p < 0.01). Re- 
sponse was most striking in patients with disabling 
and severe headaches. The average onset of relief 
was 8.8 days; 66% of patients responded within 7 
days, although some did not report a response until 
42 days after initiation of therapy. Improvement of 
migraine correlated weakly with improvement of de- 
pression (r = 0.25; p < 0.01). The authors conclud- 
ed that amitriptyline is effective in the prophylaxis of 
migraine, but that its efficacy is probably not due to 
antidepressant properties. 
The same authors then conducted a placebo- 
controlled, randomized, double-blind study of ami- 
triptyline in 100 patients with migraine.71 Twelve of 
the 53 patients in the placebo group were de- 
pressed by Hamilton and Zung scales, compared to 
8 of 47 patients in the amitriptyline group. The daily 
dose of amitriptyline was initiated at 50 mg and 
gradually increased to 100 mg over 3 weeks. Head- 
ache was evaluated as in these authors’ earlier 
study.70 Improvements in frequency, duration, and 
severity of 50% or more were noted in 55.3% of 
amitriptyline-treated patients and 34.7% of placebo- 
treated patients (p < 0.05) after 4 weeks of therapy. 
The authors showed a very weak (r = 0.32) but 
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significant (p < 0.01) correlation between improve- 
ment in depression and improvement in migraine. 
More nondepressed patients (51.9%) than de- 
pressed patients (37.5%) had improvement in mi- 
graine scores; however, suggesting a stronger anti- 
migraine effect in nondepressed patients. 
These studies demonstrate that antidepressants 
may be beneficial for the prophylaxis of tension and 
migraine headaches. Correlation between relief of 
headache and alleviation of depression was not 
strong. Pain relief occurred between 1 and 6 weeks 
of therapy in most studies, but not until after 8 weeks 
of therapy in some patients. Amitriptyline is the most 
commonly studied HCA for headache, reported to 
be effective in doses ranging from 25-200 mg daily. 
D ~ x e p i n ~ ~  and trazodone68 also may be effective, 
although additional studies are necessary. Doses 
should be started low and increased gradually to 
minimize or avoid adverse effects. The most fre- 
quently reported adverse effects of HCAs in these 
studies were drowsiness, dry mouth, tremor, and 
weight gain. Currently, no controlled trials suggest 
that the addition of a phenothiazine to HCA therapy 
is he1 pf u I. 
Arthritic Pain 
The primary cause of pain in patients with arthritis 
is inflammation of joints and surrounding structures, 
but adequate control of inflammation does not al- 
ways result in control of pain.& Arthritic pain has 
features of both acute and chronic pain; release of 
chemical mediators during the inflammatory proc- 
ess represents acute pain, and mechanical destruc- 
tion of tissues may cause chronic pain. The mecha- 
nism of action of antidepressants in this multifaceted 
disorder has yet to be elucidated. Although imipra- 
mine 150 mg daily reduced the rheumatoid factor 
titer in schizophrenic patients,72 this effect was not 
confirmed by another study.73 Antidepressants gen- 
erally are used as adjuvants to antirheumatic drugs 
in the study of arthritic pain management. 
In a 6-week, double-blind study imipramine 75 mg 
daily in divided doses as compared to placebo in 20 
patients with rheumatoid arthritis.73 Rheumatoid fac- 
tor titers, pain, joint tenderness, and depression 
(Beck depression inventory) were evaluated. Al- 
though there was no effect on rheumatoid factor, 
joint tenderness and depression improved more in 
patients receiving active treatment than in those re- 
ceiving placebo. The lack of effect on rheumatoid 
factor may have been due to the dose, which was 
lower than that used by Haydu et aL7* The authors 
noted that it was difficult to separate improvement of 
arthritis from that of depression using the Beck de- 
pression inventory, and therefore, no conclusive 
statements regarding the efficacy of imipramine in 
rheumatic pain or its association with antidepres- 
sant effect were made. 
In a multicenter, double-blind, crossover study, 
imipramine 50-75 mg daily or placebo was as- 
signed to 65 patients already using analgesics for 
pain due to rheumatoid arthritis, osteoarthritis, or 
ankylosing ~pondyl i t is .~~ Depressed patients were 
excluded from the study. Patients received 1 month 
of each treatment. Pain and stiffness were evaluated 
using a 4-point scale and a VAS. Ten patients did not 
complete the 8-week trial due to adverse effects (n 
= 5), hospitalization (n = 3), and noncompliance 
with the regimen (n = 2). In the 55 patients who 
completed the study, significant improvements in 
pain (p < 0.01), stiffness (p = 0.05), and grip 
strength (p < 0.05) were noted with imipramine 
compared to placebo. Subjective patient preference 
favored imipramine (p < 0.005). Adverse effects 
were common and included dry mouth, drowsiness, 
and constipation. 
Clomipramine 10 mg and 25 mg daily was as- 
sessed in 46 patients suffering from rheumatic pain 
in an uncontrolled trial.75 Pain and morning stiffness, 
evaluated by VAS, improved in both groups, with 
maximum response at 7 weeks. Additional analge- 
sic requirements also decreased during treatment. 
Thirty-seven patients were asked their assessment 
of response; 21 (57%) said that pain was better, 4 
(1 1 %) that it was the same, and 12 (32%) that it had 
worsened. Physicians noted improvement in 68% of 
the subjects, with no difference in response be- 
tween the two doses. Statistical significance of these 
results was not reported. Although the authors con- 
cluded that clomipramine is effective as an adjunc- 
tive analgesic in rheumatic pain, the lack of placebo 
control raises doubt about the validity of the results. 
A double-blind, placebo-controlled study of clomi- 
pramine as adjunctive treatment of rheumatic pain76 
failed to confirm the drug’s suggested efficacy.75 
Forty-nine patients with arthralgia from a variety of 
causes were assigned to either clomipramine 25 mg 
or placebo. Pain was evaluated by the patients 
using a VAS; joint tenderness was evaluated by the 
physician. These values as well as additional anal- 
gesic requirements were recorded at baseline and 
after 2, 4, and 8 weeks of treatment, with marked 
improvements in all groups. Thus, clomipramine 
was no better than placebo as an adjuvant analgesic 
in arthritic pain. 
Amitriptyline 50-75 mg daily was compared to 
placebo in 36 patients with uncontrolled rheumatoid 
arthritis pain in a 12-week, double-blind 
Pain was evaluated at weeks 0,4, 8, and 12 using a 
5-point scale. The number of inflamed joints and 
their relative size were recorded at the same time 
points. As in the study above,76 subjects in both the 
placebo and active treatment groups showed 
marked improvement. Amitriptyline was no better 
than placebo for the treatment of arthritic pain. 
Trimipramine was evaluated in a similar study of 
36 patients with rheumatoid arthritis.78 Inclusion cri- 
teria required the presence of at least minimal to 
mild depression (by the Zung scale). Trimipramine 
50-75 mg daily was given for 12 weeks, and pain 
and articular indexes were assessed as in the study 
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above.77 In contrast to the findings of ~ t h e r s , ~ ~ . ~ ~  
improvement in pain (p < 0.05) and articular index 
(p < 0.02) were greater with trimipramine group 
than with placebo; no changes were noted in de- 
pression scores. Positive results were noted by the 
fourth week of therapy. 
The efficacy of adding HCAs to existing analgesic 
therapy in the management of rheumatic disease is 
still in question. Two of the three controlled trials to 
date showed no benefit of HCAs due to marked 
placebo response. To help define the benefits of 
these drugs in arthritic conditions, additional studies 
emphasizing patient and dosage selection must be 
conducted. If a trial of HCAs is desired in an arthritic 
patient, imipramine or trimipramine may be effective 
in doses of 50-75 mg daily, with onset of action of 
about 4 weeks. 
Chronic Back Pain 
Chronic back pain has many etiologic factors. The 
origin of pain that persists after treatment of acute 
musculoskeletal and neurologic dysfunctions is not 
well u n d e r ~ t o o d . ~ ~ , ~ ~  In a large percentage of pa- 
tients with chronic back pain, degenerated disks 
appear to be the precipitating factor; however, many 
have no evidence of a pathologic disorder. There- 
fore, investigators studying the management of the 
condition have begun to focus on psychologic as 
well as physical treatment.66 Although the mecha- 
nism of action of antidepressants is difficult to delin- 
eate, since these patients have a well-documented 
psychologic profile,l7< l8 several studies have evalu- 
ated the efficacy of HCAs in chronic low back 
pain .80-85 
In a 6-week, randomized, double-blind study, 60 
clinically depressed patients (as assessed by the 
Hamilton scale) with chronic back pain were as- 
signed to receive either doxepin or placebo.80 Doxe- 
pin was initiated with a dose of 50 mg at bedtime and 
then increased to 300 mg at bedtime unless marked 
improvement or adverse effects were noted. The 
mean final dose was 200 mg. Patients were evaluat- 
ed at weeks 1, 2, 4, and 6. Measurement tools in- 
cluded VAS for evaluating pain, Hamilton scale, and 
a clinical global assessment scale for evaluating 
mood improvement. Significant decreases in fre- 
quency of pain (p = 0.05), effect of pain on activity 
(p = 0.04), and effect of pain on sleep (p = 0.02) 
were observed in the doxepin-treated group com- 
pared to the placebo group after 4 weeks of therapy. 
The severity of pain was significantly decreased (p 
= 0.01) after 6 weeks. In addition, depression was 
significantly decreased in the doxepin-treated group 
(p = 0.001), and these subjects experienced a sig- 
nificant improvement in mood (p = 0.005). 
Fifty patients with chronic low back pain were 
treated with placebo or imipramine 75 mg/day initial- 
ly and increased to 150 mg/da after 3 days.81 Seven 
Of the 48 evaluable patients were clinically de- 
pressed (Beck depression inventory). Significant 
differences in the frequency of pain (p < 0.002) and 
effect of pain on activity (p < 0.004) where noted at 
the end of 8 weeks; however, baseline and post- 
treatment Beck scores did not differ. 
A double-blind study was conducted in 30 pa- 
tients with chronic back pain who were at least mild- 
ly depressed by the Hamilton scale.82 Patients were 
randomized to receive either placebo or doxepin at 
an initial dose of 50 mg at bedtime; the dose was 
increased to 300 mg at bedtime unless marked im- 
provement or adverse effects occurred. The final 
average dosage was 2.5 mg/kg/day. Patients were 
evaluated at weeks 1, 2,4, and 6 using the Hamilton 
scale, a clinical global assessment scale, profile of 
mood states (POMS), and a VAS to evaluate seven 
aspects of pain. Significant improvement in depres- 
sion scores was seen in doxepin-treated patients 
compared to placebo-treated patients at 1 week (p 
= 0.008); improvement continued throughout the 6 
weeks. A marked decrease in the frequency of pain 
(p = 0.05), pain-associated muscle tension (p = 
0.03), and effect of pain on sleep (p = 0.003) were 
noted by week 6 in the doxepin group but not the 
placebo group. No change was seen in the con- 
sumption of additional analgesics. The authors con- 
cluded that doxepin was useful in the treatment of 
patients with chronic low back pain and depression. 
The success achieved in these trials80-82 was not 
substantiated by one group.= In a double-blind 
study, 44 patients with chronic low back pain (15 
were depressed by Beck depression inventory and 
the Middlesex Hospital questionnaire) were as- 
signed to receive either imipramine 25 mg three 
times daily or placebo for 1 month. Significant im- 
provement was not documented by VAS in any of 
the back pain measurements. This may have been 
due in part to a marked placebo response. No effect 
was noted on depression scores. 
Another study compared doxepin to desipramine 
in patients with chronic back pain and depressive 
disorders evaluated by Hamilton scale.84 In an at- 
tempt to exclude placebo responders, patients who 
reported a response during the initial 2-week place- 
bo phase were dropped from the study. The 35 pa- 
tients entering the second phase of the trial were 
treated with either doxepin or desipramine at an ini- 
tial daily dose of 50 mg. This was increased gradual- 
ly to a target dosage Of 3 mg/kg/day to complete a 4- 
week trial; average final doses of doxepin and 
desipramine were 188 mg and 173 mg, respectively. 
Weekly evaluation criteria included Hamilton scale, 
POMS, McGill inventory, clinical global inventory, 
Spielberger anxiety scale, a 1 O-point pain severity 
scale, and percentage of time pain was felt. Both 
HCAs resulted in significant improvement (p < 0.05) 
in depression and pain severity by the end of the first 
week; pain frequency decreased by the end of the 
second week. A full clinical response, defined by the 
author as a pain rating of less than 4, a 40% de- 
crease in pain severity and/or frequency, and a 
Hamilton score of 10 or below, was not seen in a 
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majority of responders until the third week of treat- 
ment. Side effects were not reported. An association 
was found between improvement in depression and 
decrease in pain severity (r = 0.61; p < 0.001) and 
between improvement in depression and decrease 
in pain frequency (r = 0.47; p < 0.003). Although 
these associations were statistically significant, the 
correlation coefficients were relatively low, signify- 
ing that the changes in severity of depression were a 
relatively minor influence on the severity and fre- 
quency of pain. This, together with the fact that 8 of 
30 patients reported a dissociation between pain 
and depression, led the author to conclude that the 
analgesic activity of HCAs is separate from the anti- 
depressant effect. Since other  investigator^^^ report- 
ed a placebo response as late as 4 weeks, a 2-week 
washout may not have been adequate to exclude 
placebo responders. 
In a similar study, this author treated 32 patients 
with chronic back pain and depressive disorders (by 
Hamilton scale).85 Again, a placebo washout was 
used to exclude placebo responders. Dosing of 
doxepin and desipramine was identical to the earlier 
Six patients dropped out secondary to per- 
ceived adverse drug effects. There was a significant 
reduction in pain frequency (p = 0.01) and depres- 
sion severity (p = 0.03), but no correlation was 
found between them. 
Antidepressants have been demonstrated to be 
effective in the management of chronic back pain. 
The most consistent responses are seen with doxe- 
pin and desipramine at doses above 150 mg daily; 
other HCAs have been less consistent in their ability 
to produce analgesia. This may be due in part to the 
use of ineffective doses in some studies. The onset 
of pain improvement was between I and 3 weeks in 
the studies reviewed; however, placebo response 
may occur as late as 4 weeks after initiation of ther- 
apy. The association between antidepressant effect 
and pain relief is still unclear. 
Cancer Pain 
Advanced cancer causes pain in up to 85% of 
patients.'O Etiologic factors include tumor infiltration 
or compression of surrounding organs, anticancer 
therapy (surgery, drugs, radiation), and factors un- 
related to neoplastic d i s e a ~ e . ' ~ ~ ~ ~  Despite the use of 
large doses of narcotic analgesics, in up to 25% of 
patients pain is inadequately managed.86 Animal 
studies demonstrated enhanced analgesia with nar- 
cotic agents when HCAs are coadministered.6-12 
Theoretically, the addition of HCAs should result in 
decreased doses of narcotics. fewer adverse ef- 
ated depression is responsive to treatment with 
HCAs and that reactive depression is more respon- 
sive to psychotherapy.22 Others believe that all pa- 
tients with cancer who exhibit depression should be 
given a trial of HCAS.~~  
Few clinical studies have been conducted to 
evaluate analgesic efficacy of antidepressants in 
cancer pain. Despite the lack of controlled studies, 
antidepressants are widely used in the oncologic 
setting because of the numerous anecdoctal reports 
that suggest e f f i c a ~ y . ~ ~ ~ ~ ~  The majority of these re- 
ports, however, are published in foreign languages. 
A survey of oncology centers in Italy documented 
that 43% of patients with cancer pain receive anti- 
depressants for analgesia; 98% of surveyed physi- 
cians documented worthwhile to good benefitsg1 
An open trial of a combination of doxepin 25-225 
mg daily and piroxicam 60-1 20 mg daily document- 
ed improvement in pain and general feeling of well- 
being in 24 of 30 patients with severe cancer pain 
uncontrolled by analgesics containing codeine or 
~xycodone .~~  The six patients dropped out due to 
complications of treatment. The 24 who completed 
the study continued with the therapy until death; 
however, 17 patients required daily administration of 
narcotic analgesics (daily dose not reported) in ad- 
dition to the study treatment. Onset of symptom im- 
provement was not reported. Although the authors 
concluded that this regimen was safe and effica- 
cious, serious adverse effects such as piroxicam- 
induced gastric perforation and gastrointestinal 
bleeding occurred in three patients despite the pro- 
phylactic use of sucralfate. 
A comparative trial of trazodone 75-225 mg daily 
and amitriptyline 25-75 mg daily as adjuvant analge- 
sics was conducted in 45 patients, 33 with cancer 
pain and 12 with other neuropathic pain.33 Pain was 
evaluated using verbal descriptors (slight, moder- 
ate, exhausting, terrible, killing). Hours of sleep, 
rest, and activity, and a variety of medication-related 
adverse effects were recorded. After 15 days of ther- 
apy, a marked decrease in pain scores was noted 
for amitriptyline and trazodone. Analgesic proper- 
ties of the two drugs were similar. Although the au- 
thors concluded that the antidepressants were ef- 
fective, the lack of placebo control raises doubts 
about the validity of the results. 
At present, too little information is available from 
which to draw conclusions regarding the usefulness 
of HCAs in the treatment of cancer pain. To docu- 
ment the clinical efficacy of antidepressants as adju- 
vant analgesics in this setting, placebo-controlled 
clinical trials must be conducted. 
Conclusion 
Antidepressants are efficacious in certain chronic 
pain syndromes such as painful diabetic neurop- 
athy, migraine headache, mixed tension-vascular 
headache, and chronic back pain. Postherpetic 
neuralgia, tension headache, and arthritis pain con- 
trol may benefit by HCA treatment, but additional 
fects, and ultimately, better pain control. 
Psychologic syndromes also accompany cancer 
pain, largely because increased pain frequency and 
intensity often signal progression of the disease. 
Although these patients have a high frequency of 
depression, it is estimated only that 6% have bio- 
chemically mediated (endogenous) depression.'' 
Some experts believe that only biochemically medi- 
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controlled studies are necessary to confirm such 
use. No controlled trials have demonstrated the an- 
algesic efficacy of HCAs in cancer pain, but some 
patients may be benefited by their use. 
When HCAs are indicated, doses should be start- 
ed low and increased gradually until relief is noted or 
adverse effects are intolerable. In the studies de- 
scribed, doses were usually given 2-3 times daily; 
however, single doses at bedtime are commonly 
used in clinical practice and may be advantageous 
for patients who experience sedation as an adverse 
effect. Onset of analgesic efficacy may occur as ear- 
ly as l day, but is more likely to be noted after 2-1 0 
weeks. Although the addition of a phenothiazine to 
the regimen is advocated by some, no controlled 
studies support this theory. 
Some investigators measured serum antidepres- 
sant levels in the patients s t ~ d i e d . ~ ~ ~ ~ ~ ~  61,80-82 Of 
these, a statistically significant correlation between 
serum antidepressant level and pain relief was 
found in only one.61 A trend toward a higher anti- 
depressant level in responders was noted in two 
~ t u d i e s , ~ ~ . ~ ~  while no correlation was observed in 
one8’ and no attempt at correlation was made in 
two.80,82 At this time data are insufficient to suggest 
that analgesia is in any way related to a specific 
serum level of a given antidepressant medication. 
This is consistent with current recommendations of 
psychiatric experts,94 who suggest that such values 
are of limited use in selected patients being treated 
for depression. 
Because of the uncomfortable side effects associ- 
ated with HCAs, such as dry mouth, drowsiness, 
constipation, urinary retention, and orthostatic hy- 
potension, these agents should be used only when 
there is a clear therapeutic indication. While it ap- 
pears that the analgesic effect of HCAs is not medi- 
ated entirely through the antidepressant action, it is 
possible that patients with an underlying depressive 
disorder may experience more profound re- 
sponses. It is important to differentiate the indication 
for treatment, since the dosage range for analgesia 
may be lower than thaf for the antidepressant effect. 
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